Polypid Ltd

NASDAQ:PYPD   3:55:03 PM EDT
0.80
0.00 (0.00%)
Earnings Announcements

PolyPid Announces Eligibility For European Medicines Agency Centralized Procedure For D-Plex₁₀₀ For The Prevention Of Surgical Site Infections In Abdominal Surgery

Published: 09/28/2022 13:17 GMT
Polypid Ltd (PYPD) - Polypid Announces Eligibility for European Medicines Agency Centralized Procedure for D-plex₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Surgery.
Polypid Ltd - D-plex100 is Eligible for Centralized Procedure Under Therapeutic Innovation Criteria.
Polypid Ltd - Intend to Discuss Data and Potential Next Steps With U.S. and Eu Regulatory Authorities in Q1 of 2023.
Polypid Ltd - Currently Further Evaluating Top-line Results of Shield I.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.36

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.32

More details on our Analysts Page.